Thursday, May 2, 2013

• Teva Pharm quarterly profit falls less than expectedat Reuters (Thu 7:23AM EDT)
• InPlay: Teva Pharma beats by $0.01, reports revs in-lineBriefing.com (Thu 7:17AM EDT)
• Teva Reports First Quarter 2013 ResultsBusiness Wire (Thu 7:00AM EDT)

Wednesday, May 1, 2013

• OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group (Wed, May 1)
• OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire (Wed, May 1)

Tuesday, April 30, 2013

• [$$] FDA Lowers Age Restriction on Plan Bat The Wall Street Journal (Tue, Apr 30)
• Teva confirms over-the-counter availability of Plan Bat theflyonthewall.com (Tue, Apr 30)
• FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and OverBusiness Wire (Tue, Apr 30)
• FDA Allows 'Morning After Pill' To Be Sold To Some Teenagers Without A Prescriptionat Forbes (Tue, Apr 30)
• Bayer Aims to Expand HealthCare PortfolioZacks (Tue, Apr 30)
• Forbes Earnings Preview: Teva Pharmaceutical Industriesat Forbes (Tue, Apr 30)
• OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group (Tue, Apr 30)
• OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentPR Newswire (Tue, Apr 30)

Monday, April 29, 2013

• Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA)at TheStreet (Mon, Apr 29)
• Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy OfficerBusiness Wire (Mon, Apr 29)

Sunday, April 28, 2013

• Teva Pharmaceuticals Is A Bitter Pill To Swallowat Seeking Alpha (Sun, Apr 28)

Friday, April 26, 2013

• Teva's 3 Biggest Challengesat Motley Fool (Fri, Apr 26)
• Orphan Drug Status for Teva/Xenon DrugZacks (Fri, Apr 26)
• Wall Street Transcript Interview with Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY)Wall Street Transcript (Fri, Apr 26)

Thursday, April 25, 2013

• Which One Should Investors Buy: The Ex-Parent or the Spin-off?at Motley Fool (Thu, Apr 25)

Wednesday, April 24, 2013

• Is Merck a Cash King?at Motley Fool (Wed, Apr 24)
• 5 Health Care Stocks On The Riseat TheStreet (Wed, Apr 24)
• Billionaire Frost’s Opko to Buy Prolor in $480 Million Dealat Bloomberg (Wed, Apr 24)
• Should You Buy Stock in Amgen After the Q1 Results Pullback?at Motley Fool (Wed, Apr 24)
• Zacks Sell List Highlights: AngloGold Ashanti, Orient-Express Hotels, Teva Pharmaceutical Industries and Cytec IndustriesZacks (Wed, Apr 24)

Add TEVA News to My Yahoo!